Medicus Pharma (MDCX) Equity Average (2024 - 2025)
Medicus Pharma (MDCX) posted Equity Average of -$488840.0 for Q4 2025, down 141.81% quarter-over-quarter from $1.2 million in Q3 2025, and down 112.33% year-on-year from $4.0 million in Q4 2024.
Medicus Pharma (MDCX) Equity Average (2024 - 2025) Analysis & Trends
Medicus Pharma (MDCX) has reported Equity Average for 2 consecutive years, with -$488840.0 the latest figure, recorded in Q4 2025.
- Equity Average for Q4 2025 came in at -$488840.0, down 112.33% year-over-year; the trailing twelve-month figure through Dec 2025 was -$488840.0 (down 112.33% YoY), and the FY2025 annual result was $1.5 million, down 27.77% from the prior year.
- Equity Average was -$488840.0 for Q4 2025 at Medicus Pharma, down from $1.2 million in the prior quarter.
- Over five years, Equity Average peaked at $5.9 million in Q3 2024 and troughed at -$488840.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 28.87 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 81.37 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -4.96 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | -488,840.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -488,840.00 |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 3.96 Mn |
| Sep 30, 2024 | 5.93 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Mar 31, 2024 | 275,745.50 |